A monoclonal antibody, currently known as SAR236553, boosted the effectiveness of atorvastatin in both low and high doses in patients with primary hypercholesterolemia.
Point out that twice as many patients taking 80 mg of atorvastatin plus SAR236553 reached the target LDL levels of less than 100 mg/dL, and more than five times as many reached the target levels of less than 70 mg/dL compared with those who took atorvastatin plus placebo.
A monoclonal antibody -- currently known as SAR236553 -- boosted the effectiveness of atorvastatin in both low and high doses in patients with primary hypercholesterolemia, results of a phase II trial indicated.
Patients taking 80 mg of atorvastatin (Lipitor) along with SAR236553 had a mean 73% reduction in LDL cholesterol at 8 weeks compared with 17% in those taking 80 mg of atorvastatin plus placebo (P<0.001), reported Evan A. Stein, MD, PhD, of the Metabolic and Atherosclerosis Research Center and Medpace Reference Laboratories, and colleagues.
Those receiving 10 mg of atorvastatin plus the investigational drug had a significant 66% drop in LDL compared with the group taking 80 mg atorvastatin plus placebo (P<0.001), according to the study published in the Oct. 31 issue of the New England Journal of Medicine.
In addition, twice as many patients taking 80 mg of atorvastatin plus SAR236553 reached the target LDL levels of less than 100 mg/dL, and more than five times as many reached the target levels of less than 70 mg/dL.
01/11/2012 : By Chris Kaiser / MedPage Today.
0 comments:
Post a Comment